Astera Labs (NASDAQ:ALAB) Stock Price Down 11.7% – Here’s What Happened

Astera Labs, Inc. (NASDAQ:ALAB)’s stock price traded down 11.7% during mid-day trading on Friday. The stock traded as low as $259.06 and last traded at $256.5710. Approximately 1,628,134 shares changed hands during trading, a decline of 68% from the average session volume of 5,065,164 shares. The stock had previously closed at $290.43.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ALAB. Jefferies Financial Group upped their target price on Astera Labs from $270.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Needham & Company LLC boosted their price objective on Astera Labs from $260.00 to $425.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Northland Securities downgraded Astera Labs from an “outperform” rating to a “market perform” rating in a research report on Friday, October 9th. Royal Bank Of Canada increased their target price on Astera Labs from $425.00 to $500.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley lifted their target price on Astera Labs from $240.00 to $335.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat.com, Astera Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $340.79.

Astera Labs Trading Down 13.8%

The firm has a market cap of $43.42 billion, a P/E ratio of 123.95 and a beta of 3.68. The business has a 50-day moving average price of $308.75 and a 200-day moving average price of $254.55.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.69 by $0.11. The business had revenue of $392.40 million during the quarter, compared to analyst estimates of $360.85 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The company’s quarterly revenue was up 104.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.44 EPS. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. On average, equities analysts anticipate that Astera Labs, Inc. will post 2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Philip Mazzara sold 6,801 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $340.50, for a total value of $2,315,740.50. Following the sale, the general counsel directly owned 96,542 shares in the company, valued at approximately $32,872,551. This trade represents a 6.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stefan A. Dyckerhoff sold 8,994 shares of Astera Labs stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.96, for a total transaction of $2,472,990.24. Following the completion of the transaction, the director directly owned 3,309 shares in the company, valued at approximately $909,842.64. The trade was a 73.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 408,558 shares of company stock valued at $127,306,034 over the last three months. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Astera Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Greenleaf Trust grew its holdings in Astera Labs by 1.8% in the second quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock worth $966,000 after purchasing an additional 36 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Astera Labs by 74.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock valued at $46,000 after purchasing an additional 41 shares during the last quarter. Integrated Advisors Network LLC lifted its holdings in shares of Astera Labs by 4.8% during the 3rd quarter. Integrated Advisors Network LLC now owns 983 shares of the company’s stock valued at $350,000 after purchasing an additional 45 shares during the last quarter. Interchange Capital Partners LLC boosted its position in shares of Astera Labs by 4.4% in the 3rd quarter. Interchange Capital Partners LLC now owns 1,187 shares of the company’s stock worth $423,000 after purchasing an additional 50 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its position in shares of Astera Labs by 2.7% in the 1st quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after purchasing an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

About Astera Labs

Astera Labs, Inc is a semiconductor and connectivity solutions company that develops hardware and software for data centers, cloud computing, and artificial intelligence infrastructure. Its products are designed to help move data between processors, memory, storage, and networking components while addressing bandwidth, latency, and system-management requirements.

The company’s portfolio includes Aries PCI Express and Compute Express Link (CXL) Smart Retimers, Taurus Ethernet Smart Cable Modules, Scorpio Smart Fabric Switches, and Leo CXL Memory Connectivity Controllers.